Dupilumab and Atopic Dermatitis Flares: An Observational Study to Identify Common Clinical Features in Patients Who Have Exacerbations Despite Biological Therapy

Dermatitis. 2024 Jan-Feb;35(1):107-109. doi: 10.1089/derm.2023.0011. Epub 2023 Mar 28.

Authors

Filomena Russo¹, Vittoria Cioppa¹, Alessandra Cartocci², Nicola Milanesi³, Angelo Massimiliano D'Erme⁴, Laura Lazzeri¹, Pietro Rubegni¹, Francesco Santi¹

Affiliations

¹ Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria alle Scotte Hospital, Siena, Italy.
² Department of Medical Biotechnology, University of Siena, Siena, Italy.
³ Allergological and Pediatric Dermatology Unit, Department of Health Sciences, University of Florence, Florence, Italy.
⁴ Unit of Dermatology, Livorno Hospital, Livorno, Italy.

PMID: 36976838
DOI: 10.1089/derm.2023.0011

No abstract available

Publication types

Observational Study
Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / adverse effects
Biological Therapy
Dermatitis, Atopic* / drug therapy
Humans
Severity of Illness Index
Treatment Outcome

Substances

dupilumab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal